IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Histologically confirmed pancreatic cancer (aspiration biopsy by fine needle \[PAAF\] by USE or biopsy guide by ECO-CT). It is mandatory the diagnostic by USE and will recommend the aspiration biopsy with this technique * Tumoural volume by TAC \< 500 cc * Aged 18 to 75 years inclusive * Eastern Cooperative Oncology Group (ECOG) performance status (PS) £ 1 * Life-expectancy of more than 12 weeks * Women of child-bearing potential must be willing to practice reliable methods of birth control to prevent pregnancy Exclusion Criteria: * Previous radiotherapy or chemotherapy for malignant disease * Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease) * Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L), platelets less than 100 x 109/L or haemoglobin less than 9 mg/dL; Prothrombin time (PT) less than 50%; Serum bilirubin greater than 2.5 times the upper limit of reference range (ULRR; Creatinine clearance less than 45 mL/min; ALT or AST greater than 2.5 times the ULRR * Active dermatoses (e.g. psoriasis, eczema) * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, or drugs with known corneal toxicity * Known, severe hypersensitivity to ZD1839 or any of the excipients of this product